eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

In AMPLIFY-EXT, in patients receiving extended treatment for prevention of recurrent DVT and PE, ELIQUIS 2.5 mg BD demonstrated superior efficacy and a comparable rate of major bleeding to placebo.1†

ELIQUIS 2.5 mg demonstrated comparable incidences of bleeding vs. placebo for:

  • Major or clinically relevant non-major bleeding: 27 patients in the ELIQUIS 2.5 mg group vs. 22 patients in the placebo group (3.2% vs. 2.7% per year); RR=1.20 (95% CI: 0.69–2.10)1

  • All bleeding: 94 patients in the ELIQUIS group vs. 74 patients in the placebo group (11.2% vs. 9.0% per year); RR=1.24 (95% CI: 0.93–1.65)2

Discover the data supporting ELIQUIS in the prevention of recurrent VTE

The full publication is available to read here

Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

* The AMPLIFY-EXT clinical trial was a 12 month, randomised, double-blind trial in 2,482 patients with VTE who had been treated for 6–12 months with standard anticoagulation therapy or had completed treatment with ELIQUIS or enoxaparin / warfarin as participants in the AMPLIFY trial and for whom there was clinical uncertainty about the benefit of continuing treatment.1
† The primary efficacy endpoint was the composite of symptomatic recurrent VTE or death from any cause – an outcome consistent with that recommended in regulatory guidelines for trials of extended treatment for venous thromboembolic diseases.1 The major safety endpoint was major bleeding.1
‡ This link is to a third-party site unaffiliated with Pfizer / BMS. Please abide by the terms of use of the site.

AMPLIFY-EXT = Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy-Extended Treatment ARR = Absolute Risk Reduction BD = Twice Daily CI = Confidence Interval DVT = Deep Vein Thrombosis N = Total number of patients in either the ELIQUIS group or the placebo group n = Number of patients with event PE = Pulmonary Embolism RR= Relative Risk RRR = Relative Risk Reduction VTE = Venous Thromboembolic Events

References

  1. Agnelli G et al. N Engl J Med 2013; 368: 699–708.
  2. ELIQUIS® (apixaban) Summary of Product Characteristics.